FDA Could Soon Limit Use of Only Drug for COVID Prevention Pemivibart may have reduced activity against growing variant KP.3.1.1, agency warns Aug 27, 2024
Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care Findings from my recent study shook me to my core Aug 26, 2024
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer News, features, and commentary about cancer-related issues Aug 16, 2024
Novel Agent for Chronic GVHD Wins FDA Approval Axatilimab achieved a 75% response rate in patients with previously treated chronic GVHD Aug 14, 2024
No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire News, features, and commentary about cancer-related issues Aug 09, 2024
IL-2 Receptor-Targeted Therapy Approved for Relapsed/Refractory CTCL New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients Aug 08, 2024
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies News, features, and commentary about cancer-related issues Aug 02, 2024
FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma Indicated for newly diagnosed patients who are eligible for stem cell transplant Jul 31, 2024
Ancient DNA May Fuel Cancer; ASCO Appeals to Oncologists; Pesticide Cancer Risk News, features, and commentary about cancer-related issues Jul 26, 2024
These Athletes Weren't Doping. Their Genes Made It Look Like They Did. Advanced sequencing revealed genetic reasons for high hemoglobin, hematocrit levels Jul 24, 2024
'Realistic Chance for Pregnancy' After Stem Cell Transplant, German Study Suggests 77% of pregnancies resulted in live births Jul 19, 2024
Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer News, features, and commentary about cancer-related issues Jul 19, 2024
Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A No factor VIII inhibitors developed among the 74 boys included in the study Jul 17, 2024
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll News, features, and commentary about cancer-related issues Jul 12, 2024
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy A third of patients who had received multiple prior lines of therapy responded, small study shows Jul 10, 2024
Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma Joseph Mikhael, MD, leads a discussion on the DREAMM-7 and DREAMM-8 trials Jul 05, 2024 video
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials News, features, and commentary about cancer-related issues Jun 28, 2024
Young Cervical Cancer, Leukemia Survivors at Greater Risk of Obstetric Complications Population-based study suggests reassurance for most, high-risk strategies for some Jun 27, 2024
Subcutaneous C5 Inhibitor Approved for PNH Longer-acting crovalimab designed for more sustained effect and less treatment burden Jun 24, 2024
EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer News, features, and commentary about cancer-related issues Jun 21, 2024
Glofitamab Regimen Improves Survival in DLBCL Granted accelerated approval last year, bispecific antibody passes its confirmatory test Jun 20, 2024
Using MRD Status to Deescalate Multiple Myeloma Therapy Joseph Mikhael, MD, leads a discussion on the findings of the MRD2STOP study Jun 20, 2024 video
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL High-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line Jun 19, 2024
Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopenia "Rapid and sustained" efficacy in 95% of pretreated patients in small trial Jun 19, 2024
Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL Undetectable MRD rates of 90% or higher, PFS of 7 years or more Jun 17, 2024
New Standard of Care in High-Risk Acute Promyelocytic Leukemia? All-trans retinoic acid plus arsenic trioxide and idarubicin improved EFS over standard Jun 17, 2024
Atezolizumab Consolidation Impresses in High-Risk DLBCL Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation? Jun 14, 2024
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma Joseph Mikhael, MD, leads a roundtable discussion on two positive phase III trials from ASCO Jun 14, 2024 video
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break? News, features, and commentary about cancer-related issues Jun 13, 2024
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy Co-mutations, viral link, potential common susceptibility emerge from two studies Jun 12, 2024
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study Second-gen ALK inhibitor induces high response rate, associated with impressive survival Jun 12, 2024
Telomerase Inhibitor Approved for MDS-Related Anemia Imetelstat indicated for lower-risk myelodysplastic syndromes with transfusion-dependent anemia Jun 07, 2024
Near-Perfect Control of Slow-Growing Lymphoma With Low-Dose Radiotherapy All but four of 24 patients had complete responses to 4 Gy, local control rate of 96% at 3 years Jun 06, 2024
'Unusual' Cancers After Pandemic; A Win in TNBC; Shortage Pauses Clinical Trial News, features, and commentary about cancer-related issues Jun 06, 2024
Star Singer's Illness; AI Imitating the Dead; Internet-Addicted Brains Health news and commentary gathered by 名媛直播 staff Jun 05, 2024
Triplet Notches Survival Win in Heavily Pretreated DLBCL Benefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant Jun 02, 2024
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma Second belantamab mafodotin-containing triplet to show potency in this setting Jun 02, 2024
Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity Jun 01, 2024
Fewer Suicides in Cancer Patients; Circadian Rhythm Boost; HIV Vaccine for Cancer? News, features, and commentary about cancer-related issues May 31, 2024
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML The benefit-risk profile could change the treatment paradigm in CML, expert says May 31, 2024
